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Introduction.This study aims to evaluate the effectiveness of Tualang honey on sperm parameters, erectile function, and hormonal
and safety profiles. Methodology. A randomized control trial was done using Tualang honey (20 grams) and Tribestan (750mg)
over a period of 12 weeks. Sperm parameters including sperm concentration, motility, and morphology were analyzed and erectile
function was assessed using IIEF-5 questionnaire. Hormonal profiles of testosterone, FSH, and LH were studied. The volunteers
were randomized into two groups and the outcomes were analyzed using SPSS version 18. Results. A total of 66 participants were
involved. A significant increment of mean sperm concentration (𝑃 < 0.001), motility (𝑃 = 0.015) and morphology (𝑃 = 0.008)
was seen in Tualang honey group. In Tribestan group, a significant increment of mean sperm concentration (𝑃 = 0.007), and
morphology (𝑃 = 0.009)was seen. No significant differences of sperm concentration, motility, andmorphology were seen between
Tualang honey and Tribestan group and similar results were also seen in erectile function and hormonal profile. All safety profiles
were normal and no adverse event was reported. Conclusion. Tualang honey effect among oligospermic males was comparable with
Tribestan in improving sperm concentration, motility, andmorphology.The usage of Tualang honey was also safe with no reported
adverse event.
1. Introduction
Infertility is a disease of the reproductive system defined by
the failure to achieve a clinical pregnancy after 12 months or
more of regular unprotected sexual intercourse [1]. Infertil-
ity is a global health problem affecting couples worldwide
with estimation of about 8 to 12% of them experiencing
some form of infertility during their reproductive life [2].
Causes of infertility include male, female, couple factors, and
unexplained causes. The male factor is usually related to
sperm abnormality, while female factors are related ovarian
dysfunction and tubal pathology [3].
Male infertility involves a complex aetiology. There are
many factors contributing to male infertility such as struc-
tural abnormality, hormonal imbalance, previous infection,
environmental factor, immunological factor, genetic factor,
systemic disease, erectile function, spermatogenic dysfunc-
tion, and idiopathic. An evaluation related to spermatogene-
sis was done bymany researchers using a variety of treatment
models to treat infertility in male [4].
Measurements of sperm quality and quantity such as
sperm concentration, spermmotility, and spermmorphology
of seminal fluid were included in the conventional semen
analysis. Normal values of semen parameters issued by
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the World Health Organisation (WHO) are generally used as
the reference values [5].
Various researches were carried out for treatment of
oligospermic males using different types of medicines, hor-
mones, vitamins, herbs, or minerals. In relation to that, many
experimental procedures were employed on animals with
various types of materials to determine their effectiveness on
spermatogenesis postulated for human use [4].
1.1. Tribestan (Tribulus terrestris). Usage of Tribulus terres-
tris (herbs) for enhancement of spermatogenesis has been
reported many years ago. Studies of Tribulus terrestris in
animals have showed intensification of spermatogenesis [6]
and increase of testosterone level [7]. Besides, Tribulus ter-
restris also has antioxidant activity [8], antimicrobial activity
[9], and antihypertensive and vasodilator effect [10]. The
first standardized preparation of Tribulus terrestris was by
Sopharma, Bulgaria; “Tribestan” was well established three
decades ago and widely used in clinical trials. Tribestan has
been recommended for the treatment of impotent and libido
disorders in male [11].
1.2. Honey. Medical use of honey was documented in many
ancient written records among Egyptians, Assyrians, Chi-
nese, Greeks, and Romans. The Holy Quran and Bible also
describe the importance of honey in human’s life and there
is one surah in Quran which is named after the bees.
Honey, naturally produced from the belly of bees, contains
not less than 181 different compounds including simple and
complex sugars, organic acids, minerals and trace elements,
vitamins, amino acids, proteins (mainly enzymes), lipids
(simple, complex, and wax), plant flavours and colouring
materials, hydrocarbons, hormones, pollens, and microor-
ganisms (yeast) [12].
Tualang honey is one of several types of honey found in
Malaysia besides Gelam and Akasia honey. Tualang honey
was named after the Tualang tree (Koompassia excelsa) where
Apis dorsata bees build their nest to produce honey. The
Tualang tree can be found in the lowland rainforest of south-
ernThailand, north-eastern Sumatra, and also Malaysia [13].
About 14–18 compounds in Tualang honey have antioxidant
properties [14].
Local research teams have evaluated the effect of Tualang
honey in various studies. In animal studies, Tualang honey
has been used in wound treatment [15–17] and as apop-
tosis inducer [18] while, in human, it has been used for
postmenopausal treatment [18–22], scar treatment [23], and
acute respiratory symptoms [24]. Mohamed et al. have used
Tualang honey in spermatogenesis studies in healthy rats and
rats exposed to cigarette smoke [25]. The studies reported
that Tualang honey enhanced spermatogenesis in both rat
samples leading to increase in the sperms and the sper-
matic counts. The testosterone hormone level also showed
significant improvement although no changes were seen in
follicular stimulating hormone and luteinizing hormone level
[25].The quality of sperms too improved with Tualang honey
and the percentage of abnormal sperms reduced significantly
[25, 26]. These results were probably due to the antioxidant
protective effect of Tualang honey as supported byMohamed
et al. who reported that Tualang honey has large amount of
antioxidant properties derived from its phenolic constituents
[14].
1.3. Justification of the Study. There were numerous studies
conducted all over theworld aiming to evaluate themedicinal
value of honey. However, there was no reported study on
the effect of honey in improvement of sperm concentra-
tion, motility, and morphology in human as well as on
erectile function and male hormone. Therefore, the main
study objective is to determine the effectiveness of Tualang
honey in improving sperm parameters, erectile function, and
hormonal profiles among oligospermic males. Data from this
study is essential for future application on the use of honey
for the treatment of male infertility and erectile function.
2. Materials and Methods
This study is an open-label randomized control trial among
male patients attending infertility clinic at two centres that
were Universiti Sains Malaysia Hospital, Kubang Kerian,
Kelantan, and International Islamic University of Malaysia,
Kuantan, Pahang, from June 2010 until December 2012. Inclu-
sion criteria were being married, having alive wife/wives,
being of age > 20 and <55 years old, and having sperm count
between 5 and 20 × 106/mL, and being literate. Exclusion
criteria were having anatomical penile deformities, history of
undescended testes, history of vasectomy or orchidectomy,
major uncontrolled psychiatric disorders, history of alcohol
or drug abuse, history of major hematological, renal, hepatic,
or bleeding disorder, stroke or myocardial Infarction within
6months, systolic blood pressure < 90 or >170mmHg and/or
diastolic blood pressure < 50 or >100mmHg, abnormal
full blood count, renal profile, or liver function test, and
uncontrolled diabetesmellitus (HbA1c> 7%) and using herbs
or drugs that could contain androgenic activity in the last
three months.
Study sample size was calculated using PS power and
sample size calculation software version 3 for all objectives
with a power of 90% and statistical significance (𝛼) of 0.05.
Considering the nonresponse rate of 10%, 34 patients were
recruited for each arm. They were assigned to either Tualang
honey or Tribestan group via computer block randomization
based on their identification card number.
2.1. Study Tools
(i) Sperm Analysis. Sperm analysis was done according to
the fourthWHOmanual sample collection and delivery.This
investigation was sent and analysed either in Universiti Sains
Malaysia Hospital or in International Islamic University of
Malaysia. The respondent underwent three days abstinence
before semen collection. The seminal fluid was collected
in a special sterile plastic container and it was sent to the
respective lab within one hour after masturbation. Sperm
analysis was done during second visit and it was repeated
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Table 1: Sperm parameter reference values according to the 4th
WHOmanual 1999.
Semen parameters Reference value
Volume (mL) ≥2
pH ≥7.2
Concentration (106/ mL) ≥20
Motility (% motile) ≥50
Morphology (% normal) ≥15∗
∗From assisted reproductive technology programmes data.
during the fourth visit after completion of 12-week study.The
sperm parameters used in this study are as showed in Table 1.
(ii) Blood Investigations.Theblood investigations done in this
study were full blood count (FBC), renal function test (RFT),
liver function test (LFT), total serum testosterone, follicular
stimulating hormone, and luteinizing hormone. About 10mL
of the respondent’s blood was taken from antecubital fossa
and sent either to Gribbles Laboratory in Kuantan, Pahang,
or to Kota Bharu, Kelantan, for analysis. Blood samples were
taken during the second and fourth visits.
(iii) Questionnaire. The questionnaire used in this study
was International Index of Erectile Function (IIEF-5). The
IIEF-5 questionnaires contain five questions for patient self-
assessment to detect and classify the severity of erectile
dysfunction. Erectile dysfunction severity was classified into
the following five categories based on IIEF-5 scores: no
erectile dysfunction (22–25), mild erectile dysfunction (17–
21), mild to moderate erectile dysfunction (12–16), moderate
erectile dysfunction (8–11), and severe erectile dysfunction
(5–7). IIEF-5 was given to the respondents in the second
and fourth visits. A validated IIEF-5 Malay version [27] was
used in this study as all the respondents understand Malay
language well.
(iv) Physical Examination. During physical examination,
the respondents were examined for height, weight, blood
pressure, pulse rate, testicular volume, cardiorespiratory, and
abdominal examination. Height and weight were measured
using Seca scale with the height being recorded in meter
(2 decimals) and the weight being recorded in kilogram
(1 decimal). Blood pressure was measured using calibrated
manual sphygmomanometer and pulse rate was counted
manually within 60 seconds. Testicular size was measured
using orchidometer. These procedures were done during the
second and fourth visits.
2.2. Study Intervention
(i) Tualang Honey. Tualang honey used in this study was col-
lected from FAMA Kedah and sterilized by gamma radiation
done before packing in a sachet form. The respondents in
Tualang honey group were given 20 grams of Tualang honey.
With an estimated adult male body weight of 75 kg, hence,
90 grams of Tualang honey was calculated. However, based
on traditional local human consumption of honey of 0.2 g/kg
body weight [25], an estimate of around 15 grams of honey
was used. Therefore, the amount of 20 grams of honey was a
reasonable dose to be taken by the respondents in this study.
(ii) Tribestan. Tribestan tablet was used in this study as a
comparator.
2.3. Study Procedure. This study was conducted in accor-
dance with Good Clinical Practice guideline and Decla-
ration of Helsinki. Approval from Human Research and
Ethics Committee for Clinical Studies of Universiti Sains
Malaysia (USM) (Reference Number: USMKK/PPP/JEPeM
[223.3.911]) was made.
All men who were involved in the study voluntarily
participated and written informed consent was taken after
a comprehensive explanation was given regarding the pro-
posed treatment involved, nature of the therapy, anticipated
benefit, and any known side effects of the therapy during
screening visit (first visit). A study information sheet was
given and they were allowed to withdraw from the study
without penalty at any time.
During the second visit, demographic data, general con-
ditions, and genitalia examination were done to exclude
structural or other treatable causes. The respondents under-
went confirmatory sperm analysis and the baseline blood
investigations (FBC, RFT, and LFT) with hormonal profiles
(total testosterone, FSH, and LH) were taken in early morn-
ing. The IIEF-5 questionnaire was given to the respondents
in this visit. The respondents who fulfilled the criteria were
randomised to either Tualang honey or Tribestan group.
The respondents in the Tualang honey group were
instructed to take 20 grams of Tualang honey early in the
morning 30 minutes before breakfast daily for 12 weeks.
Meanwhile, the respondents in the Tribestan group were
instructed to take 250mg Tribestan for three times daily
after meals for the same period of time. These medications
were dispensed to the respective group during this visit with
amount of medication given calculated based on the next
follow-up visit.
In the third visit, compliance towards medication and
medication side effects were evaluated. The respondents
were required to bring back the remaining Tualang honey
or Tribestan for compliance assessment. Medications were
supplied to the respondents to be completed for a total of 12-
week period.
In the fourth visit, all the respondents were reexamined
for their general conditions and blood investigations includ-
ing FBC, RFT, LFT, total testosterone, FSH, and LH were
repeated. Sperm analysis was repeated and erectile function
was reevaluated using IIEF-5 questionnaire.
During the fifth visit, that is, about two weeks after
completion of the study, the respondents were contacted
asking on any other adverse effects. Figure 1 showed flow
chart of the study.
2.4. Statistical Analysis. The data were analysed using Statis-
tical Package for Social Sciences (SPSS) 18.0 under license of
USM, Malaysia. In descriptive analysis, mean (SD, standard
deviation) was used to describe continuous variables while
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First visit (screening visit)
Male with oligospermia
Obtain informed consent
Second visit (week 0)
Demographic data, physical examination
Hematological, biochemical, and hormonal profiles
Sperm analysis (confirmatory)
IIEF-5 questionnaire
Inclusion and exclusion criteria were fulfilled
Randomize subjects and dispense study medication
Tribestan group (n = 34) Tualang honey group (n = 34)
Tribestan 250mg tds Tualang honey 20 g daily
Third visit (week 6)
Assessment of compliance and medication side effect
Fourth visit (week 12)
Physical examinations
Hematological, biochemical, and hormonal profiles
SFA
IIEF-5 questionnaire
Follow-up visit (week14)
Adverse effect
Figure 1: Flow chart of the study.
frequency and percentage (%) were used to describe categor-
ical. Sociodemographics and baseline medical characteristics
were compared between two groups using chi-square tests
for categorical data and ANOVA for numerical data. Paired
𝑡-test was used for comparisons between pre- and postinter-
ventions in sperm concentration, motility, and morphology
of Tualang honey and Tribestan groups. ANOVA was used
for comparison of postintervention outcomes of sperm con-
centration, motility and morphology, erectile function, and
hormonal profiles between two groups. After potential con-
founders were controlled, difference in sperm concentration,
motility and morphology, erectile function, and hormonal
profiles postintervention between two groups were analysed
using ANCOVA analysis. Repeated measure ANOVA was
used to analyse safety profiles between two groups pre- and
postintervention.𝑃 value < 0.05 was used to denote statistical
significance.
3. Results
3.1. Sociodemographic and Baseline Medical Characteris-
tics. Mean age of the respondents in Tualang honey and
Tribestan group was 34.0 and 34.9 years, respectively. Most of
the respondents in this study were Malays with only six
respondents in Tualang honey group and three respondents
in Tribestan group who were non-Malays. More than 70%
of the respondents in both groups were nonsmokers. The
respondents in Tualang honey group and Tribestan group
hadmean systolic blood pressure and diastolic blood pressure
in normotensive range. Nevertheless, mean body mass index
(BMI) of the respondents in both groups was overweight
(BMI > 25 kg/m2) with 27.4 kg/m2 in Tualang honey group
and 26.2 kg/m2 in Tribestan group.
Mean sperm concentration preintervention in Tualang
honey group was 12.4 × 106/mL and 12.9 × 106/mL in
Tribestan group. Meanwhile, sperm motility and sperm
morphology in Tualang honey group were 38.3% and 65.1%,
respectively, as compared to Tribestan group which were
40.4% and 63.0%. However, there were no statistical sig-
nificant difference in sperm parameters (sperm concentra-
tion, sperm motility, and sperm morphology) between both
groups (Table 2).
Mean IIEF-5 score among respondent in both groups
showed mild erectile dysfunction (score 17–21) with 20.1
score in Tualang honey group and 20.8 score in Tribestan
group. However, the difference was not significant. Grading
of severity of erectile dysfunction among the respondents
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Table 2: Sociodemographic and baseline medical characteristics.
Variable Tualang honey (𝑛 = 34) Tribestan (𝑛 = 32) P value
mean (SDa) 𝑛 (%) mean (SDa) 𝑛 (%)
Sociodemographic
Age (years) 34.0 (4.87) 34.9 (6.89) 0.524b
Marriage duration (years) 4.5 (2.50) 6.1 (4.31) 0.072b
Number of children 0.2 (0.39) 0.3 (0.67) 0.585b
Number of partner 1.0 (0.17) 1.1 (0.25) 0.526b
Race
Malay 28 (82.4) 29 (90.6) 0.328c
Non-Malay 6 (17.6) 3 (9.4)
Education level
Primary and secondary school 19 (55.9) 14 (43.8) 0.325c
College and university 15 (44.1) 18 (56.3)
Smoking status
Nonsmoker 24 (70.6) 23 (71.9) 0.908c
Smoker 10 (29.4) 9 (28.1)
Physical examination
SBP (mmHg) 126.2 (13.34) 121.8 (10.20) 0.137b
DBP (mmHg) 80.7 (10.04) 76.6 (7.49) 0.063b
BMI (kg/m2) 27.4 (3.56) 26.2 (3.49) 0.173b
Size of right testes (mL) 18.0 (2.90) 16.6 (3.40) 0.081b
Size of left testes (mL) 17.9 (2.93) 16.4 (3.75) 0.084b
Sperm quantity and quality
Sperm concentration (×106/mL) 12.4 (4.58) 12.9 (4.99) 0.632b
Sperm motility (%) 38.3 (20.25) 40.4 (23.69) 0.692b
Sperm morphology (%) 65.1 (23.97) 63.0 (28.30) 0.746b
Erectile function
IIEF-5 score 20.1 (2.91) 20.8 (3.47) 0.362b
Grading of erectile function
No dysfunction 19 (55.9) 24 (75.0) 0.041c
Mild dysfunction 15 (44.1) 6 (18.8)
Mild to moderate dysfunction 0 (0.0) 2 (6.2)
Hormonal profile
LH (IU/L) 6.0 (7.11) 5.1 (2.79) 0.514b
Testosterone (nmol/L) 15.1 (4.58) 15.5 (6.60) 0.745b
FSH (IU/L) 6.4 (2.86) 7.3 (3.98) 0.337b
aStandard deviation.
bANOVA.
cChi-squared test.
between Tualang honey and Tribestan group showed statis-
tically significant difference (𝑃 = 0.041).
Mean hormonal profiles of LH, testosterone, and FSH
among the respondents in both groups were quite similar.
The values of LH, testosterone, and FSH were 6.0 IU/L,
15.1 nmol/L, and 6.4 IU/L, respectively, in Tualang honey
group and 5.1 IU/L, 15.5 nmol/L, and 7.3 IU/L, respectively, in
Tribestan group.
3.2. Sperm Parameters. ANOVA showed no significant dif-
ference in sperm concentration, motility, and morphology
between Tualang honey and Tribestan groups postinter-
vention; and ANCOVA showed no significant difference
in sperm concentration, motility, and morphology between
Tualang honey and Tribestan groups when age, smoking
status, and baseline sperm concentration and motility or
morphology were included in the model (Table 3).
There were statistically significant differences between
pre- and postintervention of sperm concentration (𝑃 <
0.001), motility (𝑃 = 0.015), and morphology (𝑃 =
0.008) in Tualang honey group. However, paired 𝑡-test only
showed statistically significant difference between pre- and
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Table 3: Sperm parameters between Tualang honey and Tribestan.
Variable
ANOVA ANCOVA
Mean (SDa)
𝐹 statb P value EMM
c (95% CId)
𝐹 statb P value
Tualang Honey Tribestan Tualang Honey Tribestan
Sperm concentration (×106/mL) 31.4 (29.12) 25.3 (25.14) 0.23 0.632 30.9 (21.27, 40.53) 23.7 (13.76, 33.71) 1.18 0.281
Sperm motility (%) 48.1 (15.12) 49.8 (16.62) 0.18 0.670 47.2 (41.44, 52.93) 48.9 (42.94, 54.80) 0.18 0.670
Sperm morphology (%) 79.2 (14.80) 77.3 (10.86) 0.35 0.558 79.3 (74.53, 84.13) 77.2 (72.23, 82.16) 0.42 0.517
aStandard deviation.
b
𝐹 statistic.
cEstimated marginal mean.
dConfidence interval.
Table 4: Sperm parameters in Tualang honey and Tribestan group.
Variable
Tualang Honey Tribestan
Mean (SDa) P value Mean (SD
a) P value
Preintervention Postintervention Preintervention Postintervention
Sperm concentration (×106/mL) 12.4 (4.58) 31.4 (29.12) 0.000 12.9 (4.99) 25.3 (25.14) 0.007b
Sperm motility (%) 38.2 (20.25) 48.1 (15.12) 0.015 40.4 (23.69) 49.8 (16.62) 0.066b
Sperm morphology (%) 65.1 (24.97) 79.2 (14.80) 0.008 63.0 (28.30) 77.3 (10.86) 0.009b
aStandard deviation.
bPaired 𝑡-test.
Table 5: Erectile function between Tualang honey and Tribestan.
Variable
ANOVA ANCOVA
Mean (SDa)
𝐹 statb 𝑃 value EMM
c (95% CId)
𝐹 statb 𝑃 value
Tualang honey Tribestan Tualang honey Tribestan
IIEF-5 score 20.6 (2.81) 21.9 (2.96) 3.44 0.068 20.7 (19.94, 21.43) 21.6 (20.87, 22.42) 3.42 0.070
aStandard deviation.
b
𝐹 statistic.
cEstimated marginal mean.
dConfidence interval.
postintervention of sperm concentration (𝑃 = 0.007) and
morphology (𝑃 = 0.009) in Tribestan group (Table 4).
3.3. Erectile Function. ANOVA showed no significant differ-
ence in IIEF-5 score between Tualang honey and Tribestan
groups postintervention; and ANCOVA showed no signif-
icant difference in IIEF-5 score between Tualang honey
and Tribestan when age, smoking status, SBP, DBP, total
testosterone, and baseline IIEF-5 score were included in the
model (Table 5).
3.4.Hormonal Profiles. ANOVAshowedno significant differ-
ence in hormonal profile, that is, luteinizing hormone, total
testosterone, and follicular stimulating hormone between
Tualang honey and Tribestan groups’ postintervention.
Meanwhile, ANCOVA showed no significant difference in
hormonal profile between Tualang honey and Tribestan
groups when age and baseline hormonal levels were included
in the model (Table 6).
Themean LH decreased in both groups after 12 weeks but
no changes was seen in mean testosterone and FSH.
3.5. Safety Profiles. All safety profiles of Tualang honey
and Tribestan obtained from hematology, in renal and liver
function in pre- and postintervention were normal ranges.
Repeated measure ANOVA showed no significant difference
in haematological, renal, and liver profiles between Tualang
honey and Tribestan pre- and postintervention (Table 7).
There were no adverse effects reported from all the respon-
dents throughout the study.
4. Discussion
Various factors were involved in male infertility leading to
several studies done as it impacts the health care services and
the couples. The history of honey goes back long way with
numerous studies being conducted all over the world aiming
to evaluate the medicinal values of honey. The animal study
on Tualang honey was done to see the effect on spermato-
genesis and it was continued to evaluate spermatogenesis in
human in this study.
4.1. Sociodemographic Data and Medical Characteristics.
Most of the respondents were Malays as they constitute
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Table 6: Hormonal profile between Tualang honey and Tribestan.
Variable
ANOVA ANCOVA
Mean (SDa)
𝐹 statb 𝑃 value EMM
c (95% CId)
𝐹 statb 𝑃 value
Tualang honey Tribestan Tualang honey Tribestan
LH (IU/L) 4.4 (1.87) 4.8 (2.19) 0.73 0.397 4.4 (3.69, 5.07) 4.8 (4.09, 5.52) 0.72 0.400
Testosterone (nmol/L) 14.8 (5.64) 14.5 (5.74) 0.34 0.565 15.0 (13.60, 16.32) 14.3 (12.89, 15.69) 0.47 0.496
FSH (IU/L) 6.7 (3.48) 7.2 (4.19) 0.94 0.337 7.1 (6.48, 7.67) 6.8 (6.16, 7.39) 0.49 0.488
aStandard deviation.
b
𝐹 statistic.
cEstimated marginal mean.
dConfidence interval.
Normal value: LH, luteinizing hormone 1–12 IU/L; testosterone, testosterone hormone 6–30 nmol/L; FSH, follicular stimulating hormone 1–12 IU/L.
Table 7: Safety profiles.
Variable
Estimated marginal mean (95% CIa)
𝐹 statb 𝑃 valueTualang honey Tribestan
Preintervention Postintervention Preintervention Postintervention
Haematological profile
Hb 153.6 (149.50, 157.61) 153.0 (145.62, 160.33) 150.3 (146.13, 154.49) 143.4 (135.84, 151.00) 2.34 0.131
TWC 7.2 (6.53, 7.77) 7.2 (658, 7.84) 7.4 (6.73, 8.01) 7.4 (6.77, 8.07) 0.00 0.967
Platelet 264.3 (247.93, 280.66) 264.8 (244.44, 285.09) 248.6 (231.69, 265.43) 254.7 (233.76, 275.67) 0.45 0.505
Urea 4.5 (4.21, 4.86) 4.7 (4.29, 5.05) 4.5 (4.15, 4.82) 4.8 (4.37, 5.15) 0.33 0.567
Renal profile
Sodium 136.6 (131.24, 142.06) 139.7 (139.15, 140.26) 140.4 (134.83, 145.98) 140.2 (139.58, 140.73) 0.78 0.381
Potassium 4.3 (4.14, 4.47) 4.2 (4.02, 4.32) 4.3 (4.12, 4.45) 4.2 (4.08, 4.40) 0.43 0.513
Creatinine 89.0 (83.83, 94.11) 88.1 (83.67, 92.44) 84.7 (79.41, 90.01) 89.5 (85.01, 94.05) 3.54 0.065
Uric acid 0.4 (2.36, 2.42) 0.4 (0.36, 0.43) 0.4 (0.36, 0.42) 0.4 (0.38, 0.45) 2.29 0.135
Liver profile
Albumin 46.9 (44.99, 48.89) 45.7 (44.92, 46.55) 46.4 (44.43, 48.45) 45.5 (44.7, 46.34) 0.04 0.844
Globulin 31.2 (29.59, 32.74) 31.3 (30.12, 32.41) 31.9 (30.28, 33.53) 31.1 (29.92, 32.73) 0.65 0.425
T. bilirubin 10.4 (8.67, 12.21) 10.9 (9.24, 12.64) 10.8 (8.92, 12.58) 10.7 (8.91, 12.41) 0.35 0.558
ALP 71.2 (64.27, 78.20) 69.0 (62.43, 75.57) 73.3 (66.10, 80.46) 70.0 (63.23, 76.77) 0.14 0.712
ALT 43.3 (34.08, 52.57) 40.6 (31.75, 49.42) 45.9 (36.38, 55.43) 46.7 (37.58, 55.80) 0.85 0.360
AST 30.6 (26.03, 35.27) 28.7 (24.09, 33.33) 33.4 (28.61, 38.14) 32.5 (27.71, 37.23) 0.17 0.682
aConfidence interval.
bF statistic.
Normal value: Hb, haemoglobin 130–180 g/L; TWC, total white cells 4.0–11.0 × 109/L; platelet 150–450 × 109/L; sodium 135–145mmol/L; potassium 3.5–
5.1mmol/L; creatinine 50–116 umol/L; uric acid 0.18–0.47mmol/L; albumin 35–50 g/L; globulin 20–39 g/L; T. bilirubin, total bilirubin<21 umol/L; ALP, alkaline
phosphatase 30–150U/L; ALT, alanine transaminase <51U/L; AST, aspartate transferase <41U/L.
the major population in Kelantan and Terengganu. The
respondents in both groups have mean of BMI ≥ 23 kg/m2
and were considered as overweight. This finding showed
there was possibility of relationship between oligospermia
and BMI. Besides, obese and overweight men also have
lower sperm quality [28, 29]. The possible explanation was
due to alteration in circulation of reproductive hormone
concentration [29].
4.2. Sperm Parameters. The respondents in Tualang honey
and Tribestan group had statistically significant difference
in sperm parameters from pre- to postintervention. The
possible explanations of these findingswere antioxidant effect
of Tualang honey and Tribestan. A systematic review by
Ross et al. concludes that the use of oral antioxidant could
improve sperm concentration, motility, and morphology in
infertile male [30]. However, the standardized amount of
specific oral antioxidant used needs to be explored. Analysis
of Tualang honey by Mohamed et al. showed that phenolic
constituent amounts in this type of honey are relatively large
[14] and that will contribute to high amount of antioxi-
dant property in Tualang honey. Animal study also showed
Tualang honey had effects on oxidative stress markers and
testicular histological changes [26]. In rat exposed to oxidant
(cigar smoke), Tualang honey reduced testicular damage by
reducing lipid peroxidation and had protective effect against
abnormal sperm parameter induced by cigar smoke. It also
helps to restore antioxidant system in cigar smoke exposed
rat [26]. Besides, similar changes are also seen in Tribestan in
terms of significant improvement of sperm concentration and
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morphology.Tribulus terrestris, themain content of Tribestan
that has high antioxidant property [8] may play a role in this
effect. As a result of these, there were increments in sperm
parameter postintervention of Tualang honey and Tribestan
groups. After comparing between the groups, there were no
significant difference in all sperm parameters postinterven-
tion between Tualang honey and Tribestan group.
4.3. Erectile Function. The IIEF-5 score was used to evaluate
erectile function of the respondents. This tool was used
because it is a simple and reliable diagnostic tool for direct
assessment of males’ erection function [31]. The baseline
mean score of IIEF-5 among respondents in both groups
showed mild erectile dysfunction. However, no significant
differences in IIEF-5 mean scores at baseline were observed
between Tualang honey and Tribestan groups. In addition,
this study showed a significant difference in grading of erec-
tile function severity between Tualang honey and Tribestan
group preintervention. About 44.1% of the respondents in
Tualang honey group have mild erectile dysfunction and
the remaining are normal compared to the respondents in
Tribestan group with 6.2% being mild to moderate dysfunc-
tion, 18.8% being mild dysfunction, and 75.0% being normal.
This result could be explained by wide range of differences in
the number of respondents in each grading group leading to
significance of their differences.
The use of Tribestan in treating an erectile dysfunction
was started many years ago as documented in animal and
human studies due to the effect of the testosterone hormone
[7, 11]. However, no previous honey study has been conducted
to evaluate effect on erectile function, although increase of
testosterone hormone was seen in animal study [25]. From
the result of erectile function postintervention, there was no
significant difference between Tualang honey and Tribestan
group. However, this result could not conclude whether the
effect of Tualang honey on erectile function was similar to
Tribestan. Further research needs to be done among erectile
dysfunction men.
4.4. Hormonal Profiles. Many hormones were involved in
spermatogenesis. Physiologically, many hormones play a
role in regulating spermatogenesis especially, FSH, LH,
and testosterone. FSH gives direct effect on Sertoli cells
which produce nutrients, cofactors, and proteins that are
needed for normal spermatogenesis progression and support
transportation of spermatozoa within seminiferous tubule
lumen. Meanwhile, LH acts on Leydig cells to produce
testosterone hormone for growth and division of germinal
cells to form spermatozoa [32]. The baseline mean levels
of testosterone hormone, FSH, and LH were within normal
range and no statistically significant different was seen in
preintervention mean level of these hormones between both
groups.
Normally, oligospermia men have low testosterone hor-
mone with high FSH and LH level but there were studies that
reported normal level of testosterone in infertile men [33].
The possible explanation of normal testosterone in infertile
men was loss of germinal epithelium in testes but Leydig
cells were still intact to produce normal level of testosterone
[33]. In an animal study byMohamed et al., improvements of
testosterone hormone without changes in FSH and LH in the
rats exposed to cigar smoke were seen after administration
of Tualang honey [25]. They also explained this effect that
was possibly due to Tualang honey acting locally on testes
by restoring or improving function of Leydig cells. Study on
Tribestan effect on hormone level among healthy person by
Milanov and Taskov showed significant increase in LH and
testosterone although within the normal physiological range
[34]. Unfortunately, these similar changes were not seen in
this study.
4.5. Safety Profiles. Safety profiles are crucial and essential in
clinical trial settings. Basic safety profiles such as haematolog-
ical profile, renal profile, and liver function were assessed in
this study. Pre- andpostintervention safety profiles of Tualang
honey and Tribestan were in normal range.There was no sig-
nificant difference seen in blood parameters between Tualang
honey and Tribestan groups pre- and postintervention. Ani-
mal study in determining possible toxicity showed no acute,
subacute, or chronic toxicity with the usage of Tribulus
terrestris [35]. Potential teratogenicity and embryogenicity
also showed negative results and no potential carcinogenicity
[35]. Researchers have reported good tolerance and absence
of side effects with Tribestan [35].
4.6. Complementary and Alternative Medicine in Treating
Male Infertility. Recent study by Ismail et al. [36] showed
Eurycoma longifolia improved libido and sexual performance.
Surprisingly, strong impacts on sperm parameters like sem-
inal fluid volume and sperm motility were also seen with
E. longifolia [36]. Use of others substances like vitamin B,
folate, and vitamin C did not show any significant improve-
ment in sperm parameters [4]. There is no evidence that
empirical hormonal therapies such as human menopausal
gonadotrophin (HMG), human chorionic gonadotrophin
(HCG), androgen, antioestrogens (clomiphene and tamox-
ifen), prolactin inhibitors (bromocriptine), and steroids
improve male fertility except in certain conditions such as
low testosterone level, hypogonadism, and hyperprolacti-
naemia [4].Use of antioxidant propertiesmay benefit selected
patients but of limited use in clinical trials [4].
5. Conclusion
The effect of Tualang honey was comparable with Tribestan
in improving the sperm parameters. Tualang honey and
Tribestan showed significant difference in sperm parameters.
Hormonal profile of testosterone, FSH, and LH did not show
any significant difference in both groups.The safety profile of
Tualang honey and Tribestan showed no significant changes
in hematological, renal, or liver functions and no adverse
effect was reported. Therefore, Tualang honey and Tribestan
are comparable and safe to be consumed until 12 weeks in
oligospermic males.
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